Matthew Gevaert

  • sam patrick posted an article
    Key evidence to be presented at AACR 2020 see more

    KIYATEC, Inc. today announced that it will present data at the 2020 American Association for Cancer Research (AACR) Annual Meeting, June 22-24, revealing how its 3D cell culture models characterize ex vivo tumor response and immunoreactivity to immune checkpoint inhibitors (i.e. PD-1, PD-L1 inhibitors) in solid tumors. These emerging capabilities address a significant unmet need in both preclinical drug development and clinical decision-making in oncology.

    PD-1/L1 inhibitors have experienced meteoric growth over the last decade, offering hope to hundreds of thousands of cancer patients every year in the US alone. However, typically no more than 25-30% of eligible cancer patients who receive PD-1/L1 inhibitors actually respond to them. Given that the direct costs associated with PD-1/L1 therapy can run into the hundreds of thousands of dollars per patient, KIYATEC believes that pre-treatment, patient-specific PD-1/L1 response prediction could one day offer clinicians, patients and payers a more objective basis for determining PD-1/L1 inhibitor patient eligibility vs. today’s commonly used population-based biomarkers. 

    Evidence presented by KIYATEC at AACR 2020 will highlight findings of the company’s ability to detect dose-dependent response to checkpoint blockade and corresponding correlation with immune cell activation in high-throughput ex vivo 3D tumor spheroid models. KIYATEC believes these recent advances may represent key building blocks toward the eventual development and validation of clinical assays capable of accurate pre-treatment, patient-specific prediction of response to immuno-oncology drugs. 

    “We’re constantly innovating and expanding the capabilities of our 3D cell culture technologies to reduce the cost and risk of preclinical drug development for our immuno-oncology customers,” said Matthew Gevaert, CEO of KIYATEC. “As we continue to make these advances in immuno-oncology drug response on higher-throughput platforms, we can begin to envision a time when such capability would inform clinical decision-making for cancer patients as well.”

    KIYATEC’s poster presentations at AACR 2020 are as follows:

    Title: Multifaceted functional assessment of checkpoint inhibitor efficacy using 3D tumor spheroids

    • Abstract: 7397 / Poster: 315 / Session: 3D & Tissue Recombinant Models / June 22-24

     

    Title: PARP inhibition in combination with pembrolizumab enhances cytotoxicity in ovarian cancer patient-derived 3D spheroids

     

    Title: The perfused 3DKUBETM rare tumor assay models in vivo drug response

    • Abstract: 7132 / Poster: 2244 / Session: Immune Checkpoints 2 / June 22-24

     

    About KIYATEC, Inc.

    KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com.

  • sam patrick posted an article
    KIYATEC adds to its Board of Directors see more

    KIYATEC, Inc. today announced the appointment of Bruce Nash, MD, MBA, to its Board of Directors. Dr. Nash brings over 30 years of executive-level healthcare experience in the managed care, hospital and medical group practice settings. Currently, he serves as Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts, one of the nation’s leading health insurance plans. During his career, Dr. Nash has held executive leadership positions in both managed care (Kaiser Permanente, Capital District Physicians’ Health Plan) and healthcare (Northern Berkshire Health System, North Adams Regional Hospital) organizations. 

    Dr. Nash serves on the boards of the Blue Cross Blue Shield Foundation and the Network for Excellence in Health Innovation (NEHI), while also serving on the Board of Strategic Advisors at the Excel Venture Management Fund and the Clinical Advisory Group at the Blue Venture Fund.  He is a board-certified physician who completed his residency training at Duke University. Bruce earned his MBA in Health Sector Management from Duke University's Fuqua School of Business.

    “We are delighted to welcome Dr. Nash to KIYATEC’s Board of Directors,” said Robert Silverman, Chairman of the Board of Directors of KIYATEC. “Bruce’s relevant experience and vision as both a clinician and an expert in managed care will provide tremendous value as KIYATEC moves forward in the development of our predictive clinical tests to improve cancer patient care and outcomes.”

    The addition of Dr. Nash to the KIYATEC Board of Directors comes as the company’s evidence development efforts continue to gain momentum:

     

    About KIYATEC, Inc.

    KIYATEC leverages its proprietary ex vivo 3D cell culture platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory.  The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types

  • sam patrick posted an article
    Company making up to 71,000 RNA extractions available to testing laboratories see more

    GREENVILLE, S.C. – April 1, 2020 – KIYATEC, Inc., a clinical-stage leader in ex vivo 3D cell culture testing that supports cancer drug development and drug therapy decision-making, announced today that it is making high-throughput RNA extraction services available to clinical laboratories nationwide that are conducting COVID-19 testing. By creating additional capacity for RNA extraction, a critical component of the COVID-19 testing process, KIYATEC believes it will help testing laboratories normalize the processing and delivery of test results at a time of unprecedented testing demand and turnaround times.

    Most coronavirus tests rely on RNA extraction as the first technical step; without it, the test cannot be performed. Nationwide shortages and backlogs in the reagents and kits most often used to perform these extractions have created bottlenecks and delays that have impacted COVID-19 testing volume and throughput, thereby prompting the U.S. Food and Drug Administration (FDA) to approve alternate testing processes under Emergency Use Authorization (EAU) status. With an already CLIA-certified and operational high complexity lab, KIYATEC is joining the fight against this pandemic by offering its RNA extraction services to COVID-19 testing laboratories.

    While KIYATEC’s core business in oncology continues to occupy much of its laboratory testing capacity, the company has elected to make up to 71,000 RNA extractions available over the next two months, effective immediately, on a fee-for-service basis to COVID-19 testing laboratories nationwide. At a time when COVID-19 testing volume and turnaround times are surging, KIYATEC’s 24-hour turnaround time per RNA extraction could provide a cost-effective efficiency boost to laboratories performing these tests. Making RNA extraction services available to COVID-19 testing laboratories is consistent with KIYATEC’s core goals of improving patient care and outcomes.

    “Although KIYATEC traditionally serves the oncology community exclusively, we quickly determined that our existing technical infrastructure and capabilities in RNA extraction were ideally aligned to address this critical pressure point in the COVID-19 test process,” said Matthew Gevaert, PhD, CEO of KIYATEC. “Following discussions with public health thought leaders and COVID-19 testing laboratories, we realized that offering RNA extraction services could provide immediate help to these laboratories in overcoming possible supply chain challenges and optimizing their volume and turnaround time potential.”

    About KIYATEC, Inc.
    KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

    Contacts

    KIYATEC Inc.
    Lillia Holmes, Chief Operating Officer, 864-502-2013
    customer.service@Kiyatec.com
    www.kiyatec.com

  • sam patrick posted an article
    Test to Predict Pre-Treatment, Patient-Specific Responses see more

    GREENVILLE, S.C. – March 2, 2020 – KIYATEC, Inc. today announced that VA Portland Health Care System (VAPORHCS) has joined the growing roster of institutions participating in its 3D-PREDICT clinical study to validate the company’s test as a patient-specific predictor of response to cancer therapies for patients with glioblastoma, an aggressive form of brain cancer.

    “Glioblastoma, one of the most common and deadly forms of brain cancer, is notoriously difficult to treat. Patients and clinicians do not have the luxury of time to experiment with drug therapies they don’t know will work, so we developed our investigational glioblastoma drug response profile to help clinicians optimize therapeutic decision-making for their patients over the course of their disease,” said Matthew Gevaert, CEO of KIYATEC. “We are honored to welcome VAPORHCS to the 3D-PREDICT study and salute the important commitment to cancer clinical studies demonstrated by all VA hospitals.”

    3D-PREDICT is a prospective, open-label, non-interventional study to validate KIYATEC’s glioblastoma drug response profile, which leverages the company’s ex vivo 3D cell culture technology platform to assess pre-treatment, patient-specific response to a panel of 12 drugs most commonly used to treat patients with newly diagnosed or recurrent glioblastoma.  Details on the study can be found at https://clinicaltrials.gov/ct2/show/NCT03561207.

     

    About KIYATEC, Inc.

    KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory.  The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

  • sam patrick posted an article
    Synergistic technologies with potential to transform the standard of care and improve outcomes see more

    GREENVILLE, S.C. & PARIS, France November 18, 2019KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly aggressive form of brain cancer that afflicts more than 130,000 patients worldwide per year and is characterized by historically poor clinical outcomes. The collaboration will focus on accelerating the development and validation of their emerging technologies to improve both the selection and effectiveness of drugs commonly recommended and used to treat the disease. 

    “Relevant clinical advances that improve outcomes for patients with glioblastoma have been few and far between over the last two decades,” said Frederic Sottilini, CEO of CarThera. “Despite multimodal therapy, median survival remains around 15 months for these patients, virtually all of whom recur. Our goal is to optimize the selection and delivery of drug therapies to extend the lives of patients with glioblastoma.”

    The two companies were brought together by one of the world’s leading neuro-oncology and glioblastoma experts, John de Groot, M.D., professor and chairman ad interim, The University of Texas MD Anderson Cancer Center, who recognized the synergistic nature of their respective clinical initiatives. CarThera is currently conducting a multi-center clinical study of its novel ultrasound technology, SonoCloud-9, designed to increase the permeability of the blood brain barrier to improve the delivery of chemotherapeutic agents to the brains of patients with recurrent glioblastoma. KIYATEC is conducting a multi-center clinical study of its ex vivo 3D cell culture technology to accurately predict pre-treatment, patient-specific response to recommended standard of care cancer drugs for newly diagnosed and recurrent glioblastoma.

    “As someone who cares for patients with glioblastoma, I applaud the efforts of CarThera and KIYATEC to bring evidence-based advances to the clinic for the purpose of improving outcomes for patients with glioblastoma,” said Dr. de Groot. “I envision these two technologies as being complementary with the potential to transform the way in which neuro-oncologists manage glioblastoma patients.”

    Under the terms of the clinical collaboration, KIYATEC will conduct ex vivo drug response profiling on glioblastoma tissue samples from patients enrolled in CarThera’s clinical study. CarThera will benefit from having ex vivo drug response profiling for patients enrolled in its study, while KIYATEC will correlate its patient-specific, pre-treatment drug response predictions with actual clinical outcomes of patients in CarThera’s study. For both companies, this collaboration represents an opportunity to enrich their portfolios of clinical evidence with the goal of helping clinicians improve outcomes for their patients with glioblastoma.

    “Both of our companies are dedicated to ensuring that glioblastoma patients receive the most appropriate drug therapy at the right time, and that the efficacy of that therapy is maximized to its fullest therapeutic potential,” said Matthew Gevaert, CEO and co-founder of KIYATEC. “We believe that this clinical collaboration has the potential to help us accelerate and deliver on the long-awaited promise of personalized medicine for these deserving patients.”

    Both companies will be sending delegates to the 24th Annual Meeting of the Society for Neuro-Oncology, November 20-24 in Phoenix, Arizona.

     

    About KIYATEC, Inc.

    KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for its investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com.

     

    About CarThera

    CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders. The company is a spin-off from AP-HP, Greater Paris University Hospitals, the largest hospital group in Europe, and Sorbonne University. Since 2010, CarThera has been leveraging the inventions of Professor Alexandre Carpentier, a neurosurgeon at AP-HP who has achieved worldwide recognition for his innovative developments in treating brain disorders. CarThera developed SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB). CarThera is based at the Brain and Spine Institute (Institut du Cerveau et de la Moelle épinière, ICM) in Paris, France, and has laboratories at the Bioparc Laënnec business incubator in Lyon, France. The company, led by Frederic Sottilini (CEO), works closely with the Laboratory of Therapeutic Applications of Ultrasound (Laboratoire Thérapie et Applications Ultrasonores, LabTAU, INSERM) in Lyon.  www.carthera.eu

  • sam patrick posted an article
    KIYATEC presenting at Socierty for Immunotherapy of Cancer conference see more

    GREENVILLE, S.C. – November 5, 2019 – KIYATEC, Inc. today announced that it will present data characterizing in vitro response to checkpoint inhibitors in solid tumors, a capability that addresses an important need in preclinical development of immuno-oncology (I/O) therapies. The data will be presented at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting, to be held November 6-10 in National Harbor, MD. 

    Biologically relevant replication of complex interactions of human immune cells with tumor cells is an ongoing challenge using traditional preclinical models. Evidence presented by KIYATEC will highlight the utility of its in vitro 3D cell culture technology platform to characterize the tumor biology and immune activation and infiltration that precipitates response to checkpoint inhibitors across multiple solid tumor types. Data includes:

    • Complex 3D cultures derived from tumor cell lines or primary tumor tissue, incorporating allogeneic or autologous immune cells
    • High-throughput spheroid models used to detect dose-dependent response to checkpoint blockade and correlate with immune cell activation
    • Complex microtumor models that mirror immune cell infiltration, therapy-mediated reduction of microtumor growth and secretion of cytokines

    “KIYATEC is pioneering advances in 3D cell culture technologies to address the unmet needs of biopharmaceutical companies engaged in pre-clinical testing of their I/O compounds,” said Matthew Gevaert, CEO of KIYATEC. “Our emerging I/O models are currently being productively deployed across a number of pre-clinical initiatives and we anticipate that activity to increase as more drug developers become aware of our unique capabilities.”

    Presentation Details

    Following are key details of the SITC poster presentation:

     

    • Poster: P3
    • Title: Predicting patient response to checkpoint blockade therapy using in vitro 3D cultures
    • Date and Time:  Friday, November 8, 12:30 – 2:00 pm, 6:30 – 8:00 pm, EST

    About KIYATEC, Inc.

    KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com.

  • sam patrick posted an article
    KIYATEC closes on new round of financing see more

    GREENVILLE, SC. – May 1, 2019 – KIYATEC, Inc. today announced the initial $3 million closing of the company’s series B2 financing round. The round was led by VentureSouth and included LabCorp® (NYSE: LH).

    “This validation and confidence by our investors, coupled with the exciting progress of our clinical trials, puts us on the path toward the next phase of growth and development,” said Matthew Gevaert, CEO of KIYATEC. “We are particularly excited to welcome LabCorp as a new investor because of the depth and breadth of their expertise in oncology.  With the preclinical and clinical development strengths of LabCorp’s Covance Drug Development business, and their corporate position as a world leader in clinical testing, there is great potential synergy across the many ways KIYATEC’s technology can be used to improve cancer care.”

    Proceeds from the financing will go toward KIYATEC’s ongoing clinical study, 3D-PREDICT, to validate KIYATEC’s proprietary assay as a patient-specific predictor of response to cancer therapies for solid tumors. The test analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.

    The company has gained significant momentum in 2019.  Recently, at the 110th Annual Meeting of the American Association for Cancer Research (AACR), KIYATEC demonstrated leading capabilities in modeling and predicting response to immuno-oncology therapies including checkpoint inhibitors. On April 10, KIYATEC was one of 20 companies recognized nationally on Capitol Hill as part of the 2019 University Innovation & Entrepreneurship Showcase.  In the first quarter of 2019, KIYATEC added three clinical sites to its 3D-PREDICT study and expects to continue its momentum by adding additional sites in the second and third quarters.

     

    About KIYATEC, Inc.

    KIYATEC is dedicated to accurately modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Our predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection. Our predictive 3D models are being used by leading biopharmaceutical companies to increase the success of their preclinical and clinical drug development programs as they develop the cancer therapies of the future. www.kiyatec.com.

  • sam patrick posted an article
    KIYATEC and OHSU initiate patient enrollment into key oncology clinical trial. see more

    GREENVILLE, S.C.-- KIYATEC, Inc., today announced that Oregon Health & Science University (OHSU) Knight Cancer Institute has initiated patient enrollment into KIYATEC’s clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies for solid tumors.

    In this clinical study, the test analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically-relevant 3D microenvironment, to determine whether or not those cells respond to guideline-recommended cancer drugs. Evidence from the company’s earlier pilot study established a correlation between patient-specific predicted tumor response and actual patient clinical response to cancer therapy. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.

    At present, the OHSU Knight Cancer Institute is enrolling newly diagnosed and relapsed ovarian cancer patients into the 3D-PREDICT Study.

    “As a pioneer in personalized cancer care, the OHSU Knight Cancer Institute is deeply committed to optimizing appropriate therapy for our patients as early as possible following diagnosis, when the disease is most treatable,” said Dr. Koen De Geest, lead investigator of the clinical trial at OHSU. “Five-year survival among high-grade ovarian cancer patients is 30%, and we believe this test has the potential to help improve outcomes in the clinic.”

    “With cancer treatment, and especially ovarian cancer, time is of the essence and being able to measure patient-specific evidence of response and non-response before treatment begins can truly change the future of cancer care,” said Matthew Gevaert, CEO of KIYATEC. “We welcome OHSU to our clinical study and their participation will be integral as we work to deliver accurate predictions of patient response to cancer therapies, reducing the need for patients to undergo treatments that may not work.”

    The 3D-PREDICT study is anticipated to continue through 2022. Details on the trial can be found on https://clinicaltrials.gov/ct2/show/NCT03561207.

    About KIYATEC, Inc.
    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to therapies before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to 
    accurately predict treatment response prior to beginning treatment.

  • sam patrick posted an article
    Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors see more

    3D-PREDICT Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors

     

    GREENVILLE, SC. – June 20, 2018 – KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay (EV3D™) across several difficult-to-treat solid tumors. The 3D-PREDICT clinical study has been initiated at the Cancer Institute of Greenville Health System (GHS) with the goal of recruiting 640 patients across additional clinical sites to be added in the future.

    The 3D-PREDICT Study is a prospective, open-label, multi-institutional, non-interventional study to validate the EV3D assay for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas, which include glioblastomas (GBM). Over the next year or so, the study will expand to include patients with newly diagnosed high-grade gliomas, high-grade rare tumors and triple negative breast cancer. The primary objectives of the study are to establish correlation between assay predicted drug response and patient clinical outcomes, and to measure the potential impact of the assay on therapeutic decision-making. The study is anticipated to continue through 2022. Details on the trial can be found on ClinicalTrials.gov

    The EV3D assay platform assesses a patient’s own cancer cells within a biologically relevant 3D culture microenvironment to provide individualized response prediction to specific therapeutic agents. In this study, the therapeutic agents predicted consist of available, guideline recommended drug options for each cancer type. 

    “As an institution, we’ve supported KIYATEC’s pilot clinical studies by providing over 450 samples of cancer tissues spanning the multiple tumor types they are testing and our clinical investigators are ready to take this important next step,” said Larry Gluck, MD, Medical Director of the GHS Cancer Institute. “Patients with recurrent ovarian cancer and recurrent GBM are among those with the most challenging prognosis at every cancer center around the country. The fact that KIYATEC is offering us a new tool in these very difficult to treat populations is a needle mover for these patients coming to Greenville for their treatment.”

    Patients with these kinds of newly diagnosed and recurrent cancers simply do not have the luxury of time on their side. Their time, health and money spent on a treatment that is not working can have devastating consequences that we all want to avoid,” said Matthew Gevaert, CEO of KIYATEC. “The commencement of this clinical trial builds upon the success of our pilot studies and represents a significant milestone toward our goal of helping cancer patients receive the best treatment at the earliest possible time.”


    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

     

    About Greenville Health System

    Greenville-based Greenville Health System (GHS) has partnered with Columbia-based Palmetto Health to form a not-for-profit health care delivery system serving 1.2 million patients annually across South Carolina. The new name and graphic identity are expected to be announced later this year. GHS offers patients an innovative network of clinical integration, expertise and technologies through its academic health system, eight medical campuses, tertiary medical center, research and education facilities, community hospitals, physician practices and numerous specialty services. GHS, by itself a 1,627-bed system, is home to 16 medical residency and fellowship programs, as well as partnership efforts such as the University of South Carolina School of Medicine Greenville and the soon-opening Clemson University Center for Nursing, Health Innovation and Research. Visit www.ghs.org for more information.

  • sam patrick posted an article
    KIYATEC growth supports upcoming programs to better predict patient response to oncology drugs see more

    GREENVILLE, SC. – May 29, 2018 – KIYATEC, Inc., a privately held company changing the future of cancer care by predicting patient response to oncology drugs prior to treatment, today announced an expansion of its leadership team with the appointment of two industry veterans. Charlene Knape has joined the company as Vice President of Clinical Affairs, and Timothy Decker as Vice President Commercial Operations.

    Mr. Decker, a twenty year industry leader with a proven track record of developing and commercializing oncology diagnostic services and pharmaceuticals, has assumed responsibility for pre-launch commercial strategic development along with tactical planning and execution to drive clinical product launches. Mr. Decker held roles of increasing responsibility in strategic and tactical marketing for a decade at G.D. Searle and Abbott Laboratories before joining Genomic Health, Inc.  Over an eight year span, he played a lead role as Director and Senior Director in the global launch, marketing, reimbursement and sales of Oncotype DX molecular diagnostic tests in breast, colon and prostate cancers. Mr. Decker subsequently served as Vice President of Marketing at Castle Biosciences, Inc., where he drove corporate and pipeline strategy, as well as in-line product strategy and revenue growth for its molecular diagnostic tests in melanoma. He joins the company from Mexico City-based Grupo Fármacos Especializados, where he served as Division Head, Oncology Diagnostics, responsible for developing reimbursement pathways and securing positive coverage decisions among public and private sector payers.

    With more than 25 years of experience working with diagnostic companies, Ms. Knape is responsible for leading the clinical development programs and clinical operations for KIYATEC’s pipeline for ovarian cancer, glioblastoma, rare tumors and triple negative breast cancer. She most recently served as Senior Director, Clinical Development for Inivata, a clinical cancer genomics company utilizing liquid biopsies for comprehensive genomic profiling of tumors. Prior to this, Ms. Knape served in Becton Dickinson’s Corporate Clinical Development group, responsible for global clinical quality and contracts. Ms. Knape spent five years with Micell Technologies as Senior Director of Clinical Affairs where she managed all global clinical activities for first-in-human and CE Marking studies for an implantable cardiovascular device from initiation through successful regulatory submission. As the company’s lead in clinical operations, Ms. Knape also built the team and initiated a 1,400-patient study in Europe and a 400-patient study in China. Previously, Ms. Knape served as Vice President, Clinical Affairs at EndoTex Interventional Systems, led the clinical functions for Avocet Medical and Somnus Medical Technologies and held clinical affairs positions in the Companion Diagnostics and Biorepository at LabCorp.

    “At this pivotal time in the company’s growth, we are thrilled to welcome Charlene and Tim to KIYATEC. These two newly created positions are critical as we expand our clinical programs in key therapeutic areas and further strengthen our plan for the broad adoption of our patient-specific response prediction tests,” said Dr. Matthew Gevaert, CEO of KIYATEC. “Their expertise and industry knowledge is unparalleled and they will be instrumental as KIYATEC continues toward its path of changing the future of cancer care by predicting patient response to chemotherapy before treatment begins. I’m so glad to have Tim and Charlene on our team as we move toward our goal of commercialization and helping patients receive optimal treatment at the earliest possible time.”

    KIYATEC will be attending the American Society of Clinical Oncology (ASCO) meeting being held June 1-5 in Chicago.

    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.